Cargando…
Response to crizotinib in a patient with metastatic lung spindle cell carcinoma harboring TPM3-ROS1 fusion
Autores principales: | Cai, Cun-Liang, Zhang, Ming-Qiang, Guo, Jun, Wang, Li-Wan, Zhao, Jing-Quan, Guo, Wen-Jia, Mu, Xiang-Dong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964956/ https://www.ncbi.nlm.nih.gov/pubmed/31833905 http://dx.doi.org/10.1097/CM9.0000000000000556 |
Ejemplares similares
-
The effects of crizotinib in a transgenic Drosophila model expressing the human TPM4-ALK fusion gene or TPM4
por: Kim, Yoo Jin, et al.
Publicado: (2019) -
Combined effect of cabozantinib and gefitinib in crizotinib‐resistant lung tumors harboring ROS1 fusions
por: Kato, Yuka, et al.
Publicado: (2018) -
Characteristics of Renal Cell Carcinoma Harboring TPM3-ALK Fusion
por: Woo, Chang Gok, et al.
Publicado: (2020) -
Dual drive coexistence of EML4‐ALK and TPM3‐ROS1 fusion in advanced lung adenocarcinoma
por: Zhu, You‐cai, et al.
Publicado: (2017) -
A patient with classic biphasic pulmonary blastoma harboring CD74–ROS1 fusion responds to crizotinib
por: Meng, Zhaoting, et al.
Publicado: (2017)